Delivery Order SPE2DB22D3019-SPE2DB25FK3AN

Award Date 1/23/25
Potential Completion Date 1/24/25
Potential Value $14K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TOBRADEX EYE OINTMENT 3.5GM, a pharmaceutical product, with a ceiling value of $2,072.76 and a period of performance through March 18, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,089.15 Firm Fixed Price delivery order is for TOBREX 0.3% eye ointment, with a completion date of December 11, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products...
This federal contract award, valued at $5,434.91, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a Delivery Order, covers the procurement of Tobradex Eye Ointment 3.5 GM and is classified as Firm Fixed Price. The award has an ultimate completion date of January 6, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of TOBRADEX EYE OINTMENT 3.5GM, a specialty pharmaceutical product, with a ceiling value of $2,790.02 and a period of performance through March 10, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of TOBREX 0.3% eye ointment 3.5 grams, valued at $1,929.74. The contract is a Delivery Order awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, with a completion date of September 13, 2024. The contract is a Firm Fixed Price arrangement and does not utilize any set-aside designations. Amerisourcebergen is a major pharmaceutical distributor that holds...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,684.99, is for the procurement of TOBREX 0.3% eye ointment. The award has no set-aside designation, indicating open competition. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of Tobradex eye ointment. The $3,430.52 firm-fixed-price contract has a performance period ending on March 30, 2022. Amerisourcebergen is a major pharmaceutical distributor that holds significant Indefinite Delivery Contracts (IDCs) with the DLA Troop Support Medical and the Department of Justice Federal Bureau of Investigation, valued at up to...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,533.95, is for the supply of TOBREX 0.3% eye ointment 3.5GM to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract has a completion date of December 23, 2024 and is a firm fixed-price delivery order. This...
This federal contract award is for the delivery of Tobradex Eye Ointment 3.5 grams to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., both of which are for-profit organizations. The contract is a Delivery Order with a Firm Fixed Price valued at $5,687.92 and has an ultimate completion date of February 27, 2024. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a...
This federal contract award, with an ID of SPE2DB22D1106|SPE2DB24FEDA4, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of Tobradex Eye Ointment, 3.5 grams, with a ceiling value of $2,286.08 and a completion date of March 5, 2024. The contract is a Delivery Order under a Firm Fixed Price contract type. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp is a major...
  • SPE2DB22D3019
    Indefinite Delivery Contract
  • SPE2DB22D3019-SPE2DB25FK3AN
    Delivery Order

This federal contract award, valued at $13,926.11, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TOBRADEX Eye Ointment 3.5 GM and does not have a set-aside designation, indicating open competition.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 4/27/25, 1:01 AM